Learn vocabulary, terms, and more with flashcards, games, and other study tools.Have been hospitalized for symptoms suggestive of acute coronary syndrome that lasted at least 10 minutes at rest and occurred 48 hours or less before going to the hospital.May 15, 2017 (Final data collection date for primary outcome measure).Analysis of ANGINA PECTORIS as a potential adverse side effect of XARELTO.
Click here and search for drug information provided by the FDA.
Following an acute coronary syndrome event patients are at risk of important additional clinical events such as death, myocardial infarction, and stroke.September 2011 (Final data collection date for primary outcome measure).
The primary purpose of this study is to evaluate whether treatment with rivaroxaban and aspirin or rivaroxaban alone is better than aspirin alone in prevention of heart attacks, stroke or cardiovascular death in patients with coronary or peripheral artery disease.In some cases as a consequence of anaemia, symptoms of cardiac ischaemia like chest pain or angina pectoris have been observed.Analysis of ANGINA UNSTABLE as a potential adverse side effect of XARELTO.Subjects who are not on a PPI (proton pump inhibitor) will also be randomized to pantoprazole or pantoprazole placebo.Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number).
Complete analysis from patient reviews and trusted online health resources, including first-hand experiences. - Page 3.Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment.This disruption of blood flow can cause a heart attack, or unstable angina, a condition signifying that a heart attack may soon occur. and take XARELTO.
Study Shows Xarelto Helps Treat People Who Had Heart Attacks or Chest Pain.The statistical analysis was based on the time from randomization to the first occurrence of the event while on treatment.Xarelto is a medicine that contains the active substance rivaroxaban. Acute coronary syndrome is a group of conditions that includes unstable angina.
An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome.Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51.Choosing to participate in a study is an important personal decision.A Randomized, Double-Blind, Placebo-Controlled, Event-Driven Multicenter Study to Evaluate the Efficacy and Safety of Rivaroxaban in Subjects With a Recent Acute Coronary Syndrome.A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients With Coronary or Peripheral Artery Disease (COMPASS - Cardiovascular OutcoMes for People Using Anticoagulation StrategieS).As rivaroxaban (Xarelto) comes into wider use,. (ACS): unstable angina, non-ST elevation myocardial infarction, or ST elevation myocardial infarction.
FRAGMIN Injection is indicated for the prophylaxis of ischemic complications in unstable angina and.European Journal of Preventive Cardiology 23:13, 1401-1412. 107.Patients with coronary artery disease must also meet at least one of the following.Study found it cut odds of death and heart attack, but bleeding risk needs monitoring, experts say.